UP!

AKBA $0.33

AKBA target price
0.33
0
0

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-11-02 Future report Set alerts
Q2 2022 2022-08-04 0.23 0.23
Q1 2022 2022-05-09 -0.35 -0.35
Q4 2021 2022-03-01 -0.40 -0.40
Q3 2021 2021-11-04 -0.34 -0.34
Q2 2021 2021-08-05 -0.51 -0.51
Q1 2021 2021-05-10 -0.45 -0.45
Q4 2020 2021-02-25 -0.60 -0.60
Q3 2020 2020-11-05 -0.42 -0.42
Q2 2020 2020-08-10 -1.28 -1.28

Ratings

2016-07-12 Reiterated Rating Credit Suisse Group AG Hold
2016-05-16 Reiterated Rating HC Wainwright Buy
2016-05-08 Reiterated Rating Brean Capital Buy
2016-05-08 Reiterated Rating Morgan Stanley Buy
2016-03-16 Initiated Coverage Brean Capital Buy
2016-03-16 Lower Price Target Needham & Company LLC Buy $18.00 to $14.00
2016-03-16 Lower Price Target HC Wainwright Buy $25.00 to $18.00
2016-03-10 Lower Price Target HC Wainwright Buy $25.00 to $18.00
2016-03-10 Initiated Coverage Brean Capital Buy $26.00
2016-03-09 Lower Price Target JMP Securities Market Outperform $24.00 to $16.00
2016-03-09 Lower Price Target JPMorgan Chase & Co. Market Outperform $24.00 to $16.00
2016-01-20 Initiated Coverage Credit Suisse Neutral $10.00
2016-01-20 Initiated Coverage Credit Suisse Group AG Neutral $10.00
2015-12-15 Reiterated Rating Brean Capital Buy
2015-12-15 Boost Price Target HC Wainwright Buy $24.00 to $25.00
2015-12-14 Boost Price Target Needham & Company LLC Buy $14.00 to $18.00
2015-12-07 Initiated Coverage HC Wainwright Buy $24.00
2015-11-10 Reiterated Rating Brean Capital Buy $26.00
2015-10-06 Initiated Coverage Brean Capital Buy
2015-10-06 Reiterated Rating Needham & Company LLC Buy $14.00
2015-09-29 Reiterated Rating Brean Capital Buy $26.00
2015-09-09 Upgrade Morgan Stanley Equal Weight to Overweight $10.00 to $17.00
2015-09-09 Boost Price Target Brean Capital Buy $18.00 to $26.00
2015-08-13 Initiated Coverage Morgan Stanley Equal to Equal Weight $10.00
2015-08-12 Reiterated Rating Brean Capital Buy $18.00
2015-06-22 Initiated Coverage JMP Securities Outperform $24.00
2015-06-04 Set Price Target Brean Capital Buy $18.00
2015-05-14 Initiated Coverage Brean Capital Buy $18.00
2015-05-12 Reiterated Rating Nomura Buy $37.00 to $27.00
2015-05-12 Reiterated Rating Nomura Holdings Inc. Buy $37.00 to $27.00
2015-05-11 Initiated Coverage Needham & Company LLC Buy $14.00
2014-11-07 Reiterated Rating Nomura Buy $39.00
2014-04-14 Initiated
2014-04-14 Initiated Coverage Nomura Buy $39.00 to $16.86
2014-04-14 Initiated Coverage Credit Suisse Outperform $25.00
2014-04-14 Initiated Coverage Morgan Stanley Overweight $90.00
2016-07-12 Reiterated Rating Credit Suisse Group AG Hold
2016-05-16 Reiterated Rating HC Wainwright Buy
2016-05-08 Reiterated Rating Brean Capital Buy
2016-05-08 Reiterated Rating Morgan Stanley Buy
2016-03-16 Initiated Coverage Brean Capital Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In AKBA 0 funds of 2213 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
Novartis Bioventures Ltd 16.81%  (3405764) AKBA / CLDN / MRNA / PIP / TKAI /
Satter Muneer A 14.99%  (3037042) AKBA / TKAI / VTL /
Novo A/S SEE REMARKS 7.48%  (1516387) AKBA / ALDR / CRVS / FLXN / INGN / LPTN / OPHT / OTIC / RETA / RGDO / ZSPH /
Butler John P. President and CEO 2.02%  (408814) AKBA / KERX / RLYP /
Shalwitz Robert Chief Medical Officer 1.31%  (264556) AKBA /
Hadas Nicole R. See Remarks 0.59%  (120078) AKBA /
Dahan Michel SVP, Chief Business Officer 0.57%  (115226) AKBA /
Amello Jason SVP, CFO & Treasurer 0.43%  (87236) AKBA / OPXA / ZIOP /
Maroni Bradley SVP & Chief Medical Officer 0.32%  (64585) AKBA /
Tubridy Karen L SVP, Chief Development Officer 0.20%  (41518) AKBA / EBIO /
Jain Rita SVP, Chief Medical Officer 0.15%  (29400) AKBA /
Nash Duane 0.11%  (21499) AKBA / VTL /
Renaud Ronald C JR 0.02%  (5000) AKBA / CMRX / IDIX / PTCT /
WYZGA MICHAEL S 0.01%  (1500) AKBA / EXAS / IDIX / OMED / RDUS /
GOWEN MAXINE 0.01%  (1300) AKBA / IDRA / TRVN /